
Photon-Counting CT Improves Image Quality and Cuts Radiation Dose in Myeloma
A retrospective comparative study shows photon-counting computed tomography delivers higher image quality and reduced radiation doses in multiple myeloma patients.
mielomamultiplo.com · Multiple Myeloma

A retrospective comparative study shows photon-counting computed tomography delivers higher image quality and reduced radiation doses in multiple myeloma patients.
In the last 24 hours, several news items related to multiple myeloma have been released. In the US, the National Institutes of Health (NIH) shared data from the early stages of a treatment combining a bispecific antibody targeting BCMA for relapsed/refractory multiple myeloma. In Brazil, the state of Tocantins incorporated a high-cost medication into the treatment of this disease. In the US, a grant from Pfizer for multiple myeloma education was also announced. Furthermore, a retrospective study in the United States demonstrated that Photon-Counting Computed Tomography (CT) improves image quality and reduces radiation dose in patients with multiple myeloma. Another news item, with an unidentified origin, refers to a list of the 10 most important abstracts to be presented at ASH 2026, focusing on therapies such as CAR-T and Daratumumab. Additionally, Tempest Therapeutics acquired the rights to develop and commercialize an experimental treatment for multiple myeloma. Finally, a publication in the UK discussed the targeting of the NFIL3-MYC axis inhibition as a way to overcome therapy resistance in high-risk multiple myeloma.
Made by MielomaAI As of November 17, 2026, 3:22 PM. May contain errors: view the news and speak with your doctor.












In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.

A retrospective comparative study shows photon-counting computed tomography delivers higher image quality and reduced radiation doses in multiple myeloma patients.
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.


Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.

This article discusses how kidney transplantation can be an option for people with multiple myeloma and other diseases that damage the kidneys, but it still presents challenges. Read more →


Myeloma Paper of the Day, November 16th, Suggested by Robert Orlowski / Abhishek Gaur, Ankita Gupta, BMC Cardiovascular Disorders, Brendon Staruk, cancer,

Ben Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai,

'MRD is becoming a very valuable tool, but it's not an exclusive tool,' says expert

November 16 2026 Multiple myeloma treatment is expanding across antibody combinations CAR T cell therapies and newer immune modifying drugs Recent U S approvals have brought some options into earlier treatment lines while new subcutaneous formulations are changing how antibody ...


Tempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental treatment for myeloma.


The first administration of daratumumab was performed on a patient with multiple myeloma attended at the HGP.

/CNW/ -- Sanofi announced today the happy conclusion of negotiations with the Canadian Alliance Pharmaceutical (CPP), marked by the signing of a...


Multiple myeloma survivor, has turned his experience with the disease into a firm commitment to drive oncology research and give hope to thousands of patients. For them, it is our 2026 Woman Awards Research Prize.

Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis / BCMA, BCMA × CD3 bispecific antibody, Daratumumab, FDA

The musician from Gandia, in complete remission from his multiple myeloma which had taken him away from the stage, publishes on November 24th ‘At the Shore of Krakatoa’, a fictional story born during his treatment.

A single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.


Rafat Abonour: My Top 10 Interventional Abstracts in Multiple Myeloma and AL Amyloidosis Ahead of ASH 2026 / ASH 2026, ASH26, cancer, multiple myeloma,

Al-Ola A. Abdallah: Four Emerging Research Highlights from ASH26 / Al-Ola A Abdallah, ASH 2026, cancer care, Cancer research, Hematology, Myeloma, OncoDaily

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

Myeloma Paper of the Day, November 15th, Suggested by Robert Orlowski / Angela Dispenzieri, Blood Cancer Journal, cancer, Daniel G. Packard, David Dingli,

Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026 / American Society of Hematology (ASH), ASH 2026, cancer care, Cancer research,
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.
Discover how an innovative CAR-NK cell therapy clinical trial led to complete remission for a patient facing relapsed multiple myeloma.

Only 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.

Ralph V. Boccia, MD, FACP, explained who needs REMS certification and which care team members need training to deliver bispecific antibodies.

A laboratory study demonstrates that combining mitochondrial complex I inhibitors with proton ionophores selectively triggers apoptosis and disrupts energy balance in multiple myeloma cells in vitro.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.

My Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple Myeloma | OncLive Insights | OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.


Clinical Nurse Specialist - Myeloma at The Clatterbridge Cancer Centre NHS Foundation Trust in Liverpool. £49387-£56515. Temporary Apply on jobs24 today.

During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.

Recent advancements in multiple myeloma treatment highlight the promise of trispecific antibodies like JNJ-5322, potentially enhancing patient outcomes significantly.

Peter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…

Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.

"Lady A" country singer Charles Kelley, 45, says his multiple myeloma treatment is working, but he has been surprised by the physical toll, describing significant pain, body aches, and fatigue during his cancer journey.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.

FDA approves Mozobil for non-Hodgkin lymphoma and myeloma, and Degarelix for advanced prostate cancer.

In this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.

The Portuguese Association Against Leukaemia (APCL) is holding a seminar dedicated to multiple myeloma (MM) on November 21st, between 09:30 and 17:20, at the Conservatório de Música de Coimbra School of Arts. The event brings together patients, caregivers, doctors, and other healthcare professionals, fostering dialogue…
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.

In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.

Mehak Trehan: 10 Pivotal Myeloma Abstracts to Watch at ASH 2026 / ASH 2026, cancer care, Cancer research, Hematology, Mehak Trehan, Myeloma, OncoDaily


The event, held in an immersive course format, brought together teachers and specialist doctors in the field within a program that included lectures, visits to reference centers, and discussions about diagnostic and therapeutic approaches for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow…
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D...




Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.


Phase 1 findings support further study of MK-4002 in relapsed multiple myeloma, with early responses balanced against frequent severe adverse events.

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.



Darzalex Faspro was linked to better survival than IV Darzalex in people with multiple myeloma, according to a Medicare data analysis.

During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.

European Commission Expands Melphalan Flufenamide Approval to Third-Line Treatment for Multiple Myeloma / dexamethasone, Drug Approval, EMA, European

Philanthropy initiative targets treatment innovation

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society…

IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.

– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026...

The panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.

At the 2026 National Summit on Hematologic Cancers, Kate Kennedy, MSN, APRN, flagged decisions where guidelines give nurses and APPs little direction.

The panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Small trial, big idea.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith introduce cereblon E3 ligase modulators (CELMoDs) and discuss their dual activity in multiple myeloma.


Community hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
In this segment, Dr. Joseph Mikhael asks Dr. Scott Goldsmith to explain the evidence supporting the use of minimal residual disease (MRD) negativity as an endpoint for regulatory decision-making in multiple myeloma.

Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.

Immunotherapies and other innovations are expanding the chances of deep and lasting responses.


A targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.

Multiple myeloma survivors and caregivers helped shape a Brooklyn mural designed to bring their experiences, community connections and stories into public view.
In this segment, Dr. Joseph Mikhael, Dr. Paul Richardson, and Dr. Scott Goldsmith introduce the relationship between minimal residual disease (MRD) negativity and cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting the role of MRD-negative complete response as an emerging regulatory endpoint.

Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.

A phase 2 Sylvester trial found that CD38-targeted immunoPET can reveal active multiple myeloma missed by standard PET/CT.

Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,

Multiple myeloma (MM) is a refractory plasma cell neoplasm characterized by frequent development of drug resistance, leading to poor clinical outcomes. Activation of ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a promising cancer therapeutic strategy. In this study, we…

High-risk multiple myeloma features were associated distinct patterns of treatment failure after cilta-cel.

Experts discuss the broader use of four-drug regimens and whether treatment can be shortened

Nikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.

This Collection invites research in the field of multiple myeloma and plasma cell disorders.

On November 14th, the French Association of Multiple Myeloma Patients organizes in Annecy its 21st information day dedicated to this cancer of the...

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

The EU has approved Tecvayli as a standalone injection for people whose myeloma has returned after one prior line of treatment.


Rahul Banerjee, MD, FACP joins Petros Grivas, MD, PhD to discuss how CAR T cell-therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists, and the team approach behind it all.
The symbol brings together two stories: that of the macedotuga.com, from Vila do Conde, and that of multiple myeloma.
It is always better to be an informed patient. There is hope. There is a way forward.